Magnesium Isoglycyrrhizinate

PreclinicalSmall molecule

Magnesium Isoglycyrrhizinate is one of 12 small molecule programs targeting Hyperbilirubinemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperbilirubinemiaActive, not recruiting

HyperbilirubinemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Hyperbilirubinemia

#DrugCompanyPhaseTrials

Verazinc

FFakultas Kedokteran Universitas Indonesia

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Tricor

JJagotec

Preclinical

2 4

Legalon

BBukwang Pharmaceutical

Preclinical

1 5

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

—7

Glutathione

UUniversity of Chicago

Preclinical

1 8

E. Coli Endotoxin

RRadboud University Medical Center

Preclinical

1 9

Magnesium Isoglycyrrhizinate

CCttq

Preclinical

1 10

Bifidobacterium Animalis Subsp. Lactis

UUniversity of Sao Paulo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ARecruiting

Hyperbilirubinemia

NCT06922669

Clinical

Trials by Indication[1]

Chronic Hepatitis1 trial

Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

Unknown status·CCttq·Phase 4·NCT03349008·480 enrolled

Hyperbilirubinemia1 trial

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06922669·232 enrolled

Injury1 trial

Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury

Unknown status·CCttq·Phase 4·NCT01802996·2,040 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Magnesium Isoglycyrrhizinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Magnesium Isoglycyrrhizinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Magnesium Isoglycyrrhizinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cttq company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCttq

Magnesium Isoglycyrrhizinate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Chronic Hepatitis1 trial

Hyperbilirubinemia1 trial

Injury1 trial

References

Drug Info

Quick Facts

Related News